|
License Agreements (Details) (USD $)
|
1 Months Ended | 3 Months Ended | 9 Months Ended | 41 Months Ended | 1 Months Ended | 1 Months Ended | 9 Months Ended | 41 Months Ended | 9 Months Ended | 1 Months Ended | 9 Months Ended | 1 Months Ended | 1 Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Nov. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Dec. 31, 2011
|
Nov. 30, 2011
License agreements licensor Pfizer [Member]
|
Jun. 30, 2011
License agreements licensor Pfizer [Member]
|
Nov. 30, 2009
Up-front license payment [Member]
License Agreements Licensor Clavis Pharma [Member]
CO-101 [Member]
|
Jan. 31, 2012
Regulatory milestone payment [Member]
License agreements licensor Avila Therapeutics [Member]
CO-1686 [Member]
|
Nov. 30, 2010
License Agreement Terms [Member]
License Agreements Licensor Clavis Pharma [Member]
CO-101 [Member]
|
Sep. 30, 2012
License Agreement Terms [Member]
License Agreements Licensor Clavis Pharma [Member]
CO-101 [Member]
|
Sep. 30, 2011
License Agreement Terms [Member]
License Agreements Licensor Clavis Pharma [Member]
CO-101 [Member]
|
Sep. 30, 2012
License Agreement Terms [Member]
License Agreements Licensor Clavis Pharma [Member]
CO-101 [Member]
|
Sep. 30, 2012
License Agreement Terms [Member]
License agreements licensor Avila Therapeutics [Member]
CO-1686 [Member]
|
Apr. 30, 2012
License Agreement Terms [Member]
License Agreements Licensor Astra Zeneca U K Ltd [Member]
Rucaparib [Member]
|
Sep. 30, 2012
License Agreement Terms [Member]
License agreements licensor Pfizer [Member]
Rucaparib [Member]
|
Jul. 31, 2012
License Agreement Terms [Member]
License Agreements Licensor Array Bio Pharma Inc [Member]
License Agreements K I T [Member]
|
Nov. 30, 2009
License Agreement Terms [Member]
Up-front license payment [Member]
License Agreements Licensor Clavis Pharma [Member]
CO-101 [Member]
|
May 31, 2010
License Agreement Terms [Member]
Up-front license payment [Member]
License agreements licensor Avila Therapeutics [Member]
CO-1686 [Member]
|
Apr. 30, 2012
License Agreement Terms [Member]
Up-front license payment [Member]
License Agreements Licensor Astra Zeneca U K Ltd [Member]
Rucaparib [Member]
|
Jun. 30, 2011
License Agreement Terms [Member]
Up-front license payment [Member]
License agreements licensor Pfizer [Member]
Rucaparib [Member]
|
Nov. 30, 2010
License Agreement Terms [Member]
Payment on territory expansion [Member]
License Agreements Licensor Clavis Pharma [Member]
CO-101 [Member]
|
|
| License Agreements (Textual) [Abstract] | ||||||||||||||||||||||||
| Up-front payment | $ 15,000,000 | $ 2,000,000 | $ 250,000 | $ 10,000,000 | ||||||||||||||||||||
| Acquired in process research and development costs | 4,250,000 | 7,000,000 | 36,335,000 | 13,100,000 | 4,000,000 | |||||||||||||||||||
| Prepayment of preclinical Activities | 443,000 | 443,000 | 443,000 | 1,020,000 | 1,900,000 | |||||||||||||||||||
| Maximum licensor reimbursement of development costs incurred | 3,000,000 | |||||||||||||||||||||||
| Development costs eligible for licensor reimbursement | 15,458,000 | 11,566,000 | 40,610,000 | 28,286,000 | 105,421,000 | 0 | 3,000,000 | 3,000,000 | ||||||||||||||||
| Convertible promissory note | 7,000,000 | |||||||||||||||||||||||
| Conversion of convertible preferred stock into common stock | 2,757,788 | 551,222 | ||||||||||||||||||||||
| Interest rate on promissory note | 5.00% | 5.00% | 5.00% | 5.00% | ||||||||||||||||||||
| Principal balance and all accrued and unpaid interest on notes converted to common stock | 7,200,000 | |||||||||||||||||||||||
| Future expected development and regulatory payment | 115,000,000 | 119,000,000 | 700,000 | |||||||||||||||||||||
| Sales milestone payments | 445,000,000 | 120,000,000 | ||||||||||||||||||||||
| Future expected development, regulatory and sales milestone payments | $ 259,000,000 | $ 192,000,000 | ||||||||||||||||||||||